Results 241 to 250 of about 18,497,895 (269)

Dose‐dependent hepatotoxicity of hydrogen peroxide in HepG2 cells and its modulation by CYP450 induction

FEBS Open Bio, EarlyView.
NMR metabolomics revealed concentration‐dependent metabolic perturbations in HepG2 cells exposed to H2O2. Rifampicin pretreatment enhanced metabolic competence, attenuated toxin‐induced alterations and produced metabolite profiles more consistent with human liver physiology, supporting the use of CYP450‐induced HepG2 models for improved in vitro ...
Maren Jinks, Garth L. Maker, Emily C. Davies, Berin A. Boughton, Samantha Lodge   +4 more
wiley   +1 more source

Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development. [PDF]

J Clin Pharmacol
Oberoi RK, Peer CJ, Tripathi A, Mohammad AS, Sun Y, Der K, Song Y, Huang J, Upreti VV.   +8 more
europepmc   +1 more source

Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model

FEBS Open Bio, EarlyView.
This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito, Haduki Asano, Ayano Ueki, Joe Sakamoto, Yasuhiro Kamei, Hayato Tokumoto, Ayaka Yazawa, Shigeki Kamitani   +7 more
wiley   +1 more source

Artificial intelligence and multiomics integration for Parkinson's disease drug development. [PDF]

Mol Cells
Lee S, Kim J, Jung HU, Kim D, Cho E, Kim YJ, Ji YR, Go Y, Song P, Oh YS, Yoon JH.   +10 more
europepmc   +1 more source

Gaps in AI-Driven Pharmacokinetic Property Prediction for Early Drug Development: A Scoping Review. [PDF]

J Chem Inf Model
Tomin L, Bodaghi-Namileh V, Schwartz DG, Samudrala R, Falls Z.   +4 more
europepmc   +1 more source

A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate. [PDF]

J Antimicrob Chemother
Hendrickx S, Ilbeigi K, Thoré ESJ, Bertram MG, Calvo-Alvarez E, Cintesun S, Olías-Molero AI, Corral MJ, Mateo-Barrientos M, Estaquier J, Pomel S, Alunda JM, Gul S, Van Bocxlaer K, Frézard F, Tavares J, Cordeiro Da Silva A, Costi MP, Maes L, Caljon G.   +19 more
europepmc   +1 more source

Human-in-the-loop reconsidered: Shadow use and reliance management in drug development. [PDF]

Glob Health Med
Inoue Y.
europepmc   +1 more source

New Frontiers of Drug Development Through the Use of New Approach Methodologies. [PDF]

AAPS J
Martinez MN, Mochel JP, Allenspach K, Zdyrski C, Krishna S, Rusyn I.   +5 more
europepmc   +1 more source

Priorities for local immunotherapy research and drug development. [PDF]

J Immunother Cancer
Isaacs JM, Luke J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Cortes J, Roberto Carmagnani Pestana   +2 more
exaly